Jupiter Topco LLC Makes New $6.63 Million Investment in Axsome Therapeutics, Inc. $AXSM

Jupiter Topco LLC purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 27,079 shares of the company’s stock, valued at approximately $6,631,000.

Other institutional investors have also modified their holdings of the company. J. Goldman & Co LP purchased a new stake in shares of Axsome Therapeutics during the second quarter worth $5,633,000. ABS Investment Management LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at $171,339,000. Hsbc Holdings PLC purchased a new position in Axsome Therapeutics in the second quarter valued at $13,667,000. PDT Partners LLC purchased a new position in Axsome Therapeutics in the second quarter valued at $514,000. Finally, Palisade Capital Management LP acquired a new position in Axsome Therapeutics during the 2nd quarter worth $6,153,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $199.02 on Monday. Axsome Therapeutics, Inc. has a 1-year low of $112.90 and a 1-year high of $260.19. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The stock has a market cap of $10.42 billion, a PE ratio of -53.07 and a beta of 0.65. The stock’s fifty day moving average is $227.43 and its two-hundred day moving average is $206.89.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The business had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft set a $280.00 price target on Axsome Therapeutics in a report on Tuesday, May 5th. Needham & Company LLC upped their target price on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Friday, July 17th. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $310.00 price target for the company. Finally, UBS Group reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday, August 24th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.60.

Insider Activity

In other Axsome Therapeutics news, CFO Nick Pizzie sold 33,000 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total value of $7,922,970.00. Following the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at $10,291,938.03. This represents a 43.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark Coleman sold 643 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the sale, the director directly owned 30,389 shares in the company, valued at approximately $7,566,861. The trade was a 2.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 188,766 shares of company stock valued at $43,903,086 over the last 90 days. Insiders own 20.60% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.